Amgen To Acquire Privately-Held Dezima Pharma

Strengthens Amgen s Cardiovascular Portfolio With Late-Stage, Oral CETP Inhibitor THOUSAND OAKS, Calif. and NAARDEN, Netherlands, Sept. 16, 2015, NASDAQ, AMGN, /PRNewswire/ Amgen (NASDAQ: AMGN) and Dezima Pharma B.V. (Dezima) today announced that the companies have entered into a definitive acquisition agreement under which Amgen will acquire Dezima, a privately-held, Netherlands-based biotechnology company focused on developing innovative treatments for dyslipidemia. Dezima shareholders have approved the agreement. With the recent launches of Repatha™ (evolocumab) and Corlanor® (ivabradine), and today s acquisition of Dezima, Amgen is proud to be on the leading edge of an exciting new wave of treatments for cardiovascular disease, an illness impacting millions of people worldwide, said Robert A. Bradway, chairman and chief executive officer at Amgen. Dezima s lead molecule is TA-8995, an oral, once-daily cholesteryl ester transfer protein (CETP) inhibitor. In a Phase 2b clinical
http://bit.ly/1KpSzdH

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: